CŌRE Diagnostics partners with Digistain to bring Uk’s AI breast cancer tech to India

Revolutionary AI-enabled solution aims to improve diagnostic accuracy and reduce unnecessary chemotherapy in South Asia

Image-Dinesh Chauhan, CEO, CORE Diagnostics.
New Delhi: CŌRE Diagnostics has announced an exclusive partnership with Digistain® to introduce the UK’s first Breast Cancer Risk Profiling Technology to India, Nepal, Bhutan, and Bangladesh. This collaboration aims to bring the revolutionary digital cancer grading and prognosis solution, Digistain®, to South Asia.
The introduction of Digistain® in India and neighboring countries are expected to revolutionize breast cancer treatment by enhancing diagnostic accuracy, reducing treatment costs, and ultimately saving lives. This initiative aligns with India’s broader healthcare goals of leveraging innovative solutions to address pressing healthcare challenges and improve patient care nationwide.
Dinesh Chauhan, CEO of CŌRE Diagnostics, has over 25 years of experience in the diagnostics industry. He has been pivotal in introducing innovative tests to India and creating markets for them. His leadership will be crucial in bringing Digistain® to India.
“This partnership represents a significant step forward in the fight against breast cancer by providing a faster, more accurate, and cost-effective approach to cancer prognosis and treatment. CŌRE Diagnostics and Digistain® are committed to improving patient outcomes and transforming the landscape of healthcare,” said Chauhan.
Dr. Hemmel Amrania, CEO of Digistain®, has been key in developing this technology. With a clinical science background from Imperial College and Université Paris XI, his award-winning research has led to a novel diagnostic method that greatly improves early-stage cancer patient outcomes.
Digistain®, approved by the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA), offers a rapid, affordable, and AI-enabled method to predict the likelihood of post-surgery breast cancer recurrence. This cutting-edge technology is designed to reduce unnecessary chemotherapy for breast cancer patients, providing a significant advancement in patient care.
Developed with the input of over 1,500 oncologists and successfully trialled at prestigious institutions such as Nottingham University NHS Trust, the National Institute of Healthcare Research (NIHR), and Cancer Research UK, Digistain® has been thoroughly vetted by the National Health Service (NHS). This endorsement underscores the reliability and safety of Digistain’s technologies, meeting the rigorous standards of healthcare professionals and patients.